Cargando…

The IL-33/sST2 Axis in Thromboangiitis Obliterans

BACKGROUND: Until recently, it remains unknown whether thromboangiitis obliterans (TAO) is a type of systemic vasculitis. A high level of IL-33 and its soluble decoy receptor sST2 in the acute phase of systemic vasculitis has been demonstrated. METHODS: The serum level of IL-33 and sST2 in 50 TAO pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharebiani, Hiva, Mohareri, Mehran, Mirhosseini, Ali, Fazeli, Bahare
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371438/ https://www.ncbi.nlm.nih.gov/pubmed/32765040 http://dx.doi.org/10.2147/JIR.S253980

Ejemplares similares

Thromboangiitis obliterans episode: autoimmune flare-up or reinfection?
por: Mohareri, Mehran, et al.
Publicado: (2018)

The Imbalance among Oxidative Biomarkers and Antioxidant Defense Systems in Thromboangiitis Obliterans (Winiwarter-Buerger Disease)
por: Sharebiani, Hiva, et al.
Publicado: (2020)

Unexpected inflammation in the sympathetic ganglia in thromboangiitis obliterans: more likely sterile or infectious induced inflammation?
por: Mousazadeh, Behzad, et al.
Publicado: (2019)

Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences
por: Fazeli, Bahare, et al.
Publicado: (2021)

Visceral bed involvement in thromboangiitis obliterans: a systematic review
por: Fakour, Faeze, et al.
Publicado: (2019)

Assessment of T helper 17-associated cytokines in thromboangiitis obliterans
por: Keramat, Shayan, et al.
Publicado: (2019)

Thromboangiitis Obliterans
Publicado: (1953)

Thromboangiitis obliterans (Buerger's disease)
por: Arkkila, Perttu ET
Publicado: (2006)

Thromboangiitis obliterans (Buerger's disease)
por: Rivera-Chavarría, Ignacio J., et al.
Publicado: (2016)

Thromboangiitis Obliterans (Buerger's Disease)
por: Sinclair, Nicholas R., et al.
Publicado: (2015)

Thromboangiitis obliterans in two brothers
por: LI, QI-LIN, et al.
Publicado: (2013)

Thromboangiitis obliterans (Buerger disease)
por: Seebald, Jessica, et al.
Publicado: (2015)

Long-term outcomes of large artery thromboangiitis obliterans and comparison with small artery thromboangiitis obliterans
por: Lee, Sang Ah, et al.
Publicado: (2022)

Effect of revascularization on IL-6 and TNF-α in patients with thromboangiitis obliterans
por: Wu, Shifeng, et al.
Publicado: (2018)

Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan
por: De Haro, Joaquin, et al.
Publicado: (2012)

Circulating Angiogenic Factors in Patients with Thromboangiitis Obliterans
por: Hewing, Bernd, et al.
Publicado: (2012)

Thromboangiitis Obliterans (Buerger's Disease)—Current Practices
por: Vijayakumar, Abhishek, et al.
Publicado: (2013)

Intestinal thromboangiitis obliterans: a case report
por: Mishra, Swastik Sourav, et al.
Publicado: (2021)

The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (Thromboangiitis Obliterans)
por: Beigi, Ali Akbar, et al.
Publicado: (2014)

Measurement of Interleukin-33 (IL-33) and IL-33 Receptors (sST2 and ST2L) in Patients with Rheumatoid Arthritis
por: Hong, Yeon-Sik, et al.
Publicado: (2011)

The Association of Serum IL-33 and sST2 with Breast Cancer
por: Yang, Zhi-Ping, et al.
Publicado: (2015)

Thromboangiitis Obliterans: Changing Demographics for a Preventable Disease
por: Stefancik, Ryan
Publicado: (2019)

Cerebral venous and sinus thrombosis with complicating thromboangiitis obliterans
por: Einsiedler, Stefan, et al.
Publicado: (2021)

Clinical Presentation and Treatment of Thromboangiitis Obliterans With Superimposed Osteomyelitis
por: Kidron, Ariel, et al.
Publicado: (2022)

Thromboangiitis Obliterans: 110 Years Old and Little Progress Made
por: Olin, Jeffrey W.
Publicado: (2018)

Effects of aspirin combined with cilostazol on thromboangiitis obliterans in diabetic patients
por: Yong, Jun, et al.
Publicado: (2018)

Retinal Artery Occlusion Secondary to Buerger's Disease (Thromboangiitis Obliterans)
por: Eris, Erdem, et al.
Publicado: (2017)

Buerger's Disease in the Testicle: A Case of Testicular Thromboangiitis Obliterans
por: Harwood, Emma A, et al.
Publicado: (2023)

Predictive value of serum VEGF, IL-1 and TNF-α in the treatment of thromboangiitis obliterans by revascularization
por: Li, Zheng-Fei, et al.
Publicado: (2020)

The Potential Role of Antioxidants in the Treatment of Peripheral Arterial Disease: A Systematic Review
por: Keramat, Shayan, et al.
Publicado: (2022)

Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure
por: Firouzabadi, Negar, et al.
Publicado: (2020)

Management of thromboangiitis obliterans using distraction osteogenesis: A retrospective study
por: Kulkarni, Sunil, et al.
Publicado: (2011)

Management of thromboangiitis obliterans using distraction osteogenesis: A retrospective study
por: Marwah, Vikram
Publicado: (2012)

Psychiatric sequelae of thromboangiitis obliterans: a case report and review of the literature
por: Awara, Mahmoud A., et al.
Publicado: (2023)

Early Diagnosis and Intervention Are Needed for a Reasonable Prognosis of Thromboangiitis Obliterans
por: Bae, Miju, et al.
Publicado: (2023)

Alteration of the IL-33-sST2 pathway in hypertensive patients and a mouse model
por: Yin, Xiaoyun, et al.
Publicado: (2019)

The Clinical Significance of Serum IL-33 and sST2 Alterations in the Post-Stroke Depression
por: Xu, Meirong, et al.
Publicado: (2021)

End stage renal disease caused by thromboangiitis obliterans: a case report
por: Yun, Hyo-Jin, et al.
Publicado: (2015)

Buerger's disease (thromboangiitis obliterans): clinical features and assessment by colour duplex ultrasound
por: Busch, Kathryn
Publicado: (2015)

Platelet microparticle levels: a biomarker of thromboangiitis obliterans (Buerger’s disease) exacerbation
por: Darnige, L, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_6p844480f7jkp3iolpbive1b1c